Psilocybin Macrodose Therapy — Psychedelics & Neuroplasticity
Supervised high-dose psilocybin for profound neuroplasticity, mystical experience, depression, anxiety, and end-of-life distress — the most studied classical psychedelic in modern clinical trials.
Overview
Psilocybin is a naturally occurring prodrug converted to psilocin by alkaline phosphatase, acting as a potent 5-HT2A receptor agonist. Modern clinical research since the 2000s (Johns Hopkins, NYU, Imperial College London, COMPASS Pathways) has established compelling evidence for psilocybin in treatment-resistant depression, major depressive disorder, cancer-related anxiety, smoking cessation, and OCD. The landmark Johns Hopkins MDD study (2020, JAMA Psychiatry) found 71% response rate and 54% remission at 4 weeks with 2 guided psilocybin sessions. COMPASS COMP360 Phase IIb trial (n=233, NEJM 2022) showed 25mg produced significant depression score reduction vs placebo. Imperial College demonstrated that psilocybin disrupts the Default Mode Network (DMN) — the rumination center associated with depression — creating a transient 'reset' that enables new cognitive and emotional perspectives to form. The subjective 'mystical experience' intensity during the session is the strongest predictor of therapeutic outcome. FDA has granted Breakthrough Therapy Designation for psilocybin in MDD and TRD.
Indications
- Treatment-resistant depression (2+ failed antidepressants)
- Major depressive disorder as primary or adjunct treatment
- Cancer-related anxiety and existential distress
- PTSD (adjunct to trauma-focused therapy)
- Smoking cessation (Hopkins 80% abstinence at 6 months)
- Cluster headaches (anecdotal and case series evidence)
Mechanism of Action
Psilocin binds and activates serotonin 2A receptors throughout the cortex, particularly in layer V pyramidal neurons, causing glutamate release, cortical hyperexcitability, and profound alterations in perception and cognition
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Psilocybin (clinical trial grade) | 25 mg | Single session or 2 sessions 1-2 weeks apart | COMPASS COMP360 dosing; most trials use 20-30 mg; session lasts 5-7 hours with trained therapist present |
| Psilocybin mushrooms (harm reduction) | 3-5g dried Psilocybe cubensis (approx 10-15mg psilocybin equivalent) | Every 3-6 months maximum | Harm reduction context; profound effects; potency varies significantly by strain and batch |
Evidence Grade
GRADE C
Safety & Contraindications
- Absolute contraindications: personal or first-degree family history of schizophrenia, bipolar I, or psychosis risk
- Cardiovascular: transient hypertension and tachycardia during session — avoid in severe cardiovascular disease
- Serotonin syndrome risk: never combine with MAOIs, SSRIs, SNRIs, or lithium
- Set and setting are critical — safe environment, experienced guide/therapist mandatory
- Challenging experiences ('bad trips') occur in 30-40% of sessions but are manageable with proper support
- Psychological destabilization possible in vulnerable individuals — thorough screening required
- Legal status: Schedule I in USA; legal in Oregon (Measure 109), Colorado (Prop 122), Netherlands (truffles); clinical trial access available